Oral Session 1-13C Transplant Outcomes (1)

[OS1-13C-7] Allo-HSCT at the 1st remission for AML with FLT3-ITD; results from the JALSG AML209-FLT3-SCT study

Naomi Kawashima¹, Yuichi Ishikawa¹, Yoshiko Atsuta², Masashi Sawa³, Yukiyasu Ozawa⁴, Masaki Hayashi⁵, Akio Kohno⁶, Akihiro Tomita⁷, Tomoya Maeda⁸, Emiko Sakaida⁹, Kensuke Usuki¹⁰, Maki Hagihara¹¹, Heiwa Kanamori¹², Hiroshi Matsuoka¹³, Miki Kobayashi¹⁴, Norio Asou⁸, Shigeki Ohtake¹⁵, Itaru Matsumura¹⁶, Yasushi Miyazaki¹⁷, Tomoki Naoe¹⁸, Hitoshi Kiyoi¹ (1.Department of Hematology and Oncology, Nagoya University, 2.Japanese Data Center for Hematopoietic Cell Transplantation, 3.Department of Hematology and Oncology, Anjo Kosei Hospital, 4.Department of Hematology, Japanese Red Cross Nagoya First Hospital, 5.Department of Hematology, Nakagami Hospital, 6.Department of Hematology and Oncology, JA Aichi Konan Kosei Hospital, 7.Department of Hematology, Fujita Health University, 8.Department of Hemato-Oncology, International Medical Center, Saitama Medical University, 9.Department of Hematology, Chiba University Hospital, 10.Department of Hematology, NTT Medical Center Tokyo, 11.Department of Hematology and Clinical Immunology, Yokohama City University Hospital, 12.Department of Hematology, Kanagawa Cancer Center, 13.The Division of Medical Oncology and Hematology, Kobe University Hospital, 14.Department of Hematology, Japanese Red Cross Nagoya Daini Hospital, 15.Kanazawa University, 16.Department of Hematology and Rheumatology, Faculty of Medicine, Kindai University, 17.Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University, 18.Department of Hematology, National Hospital Organization Nagoya Medical Center)